180 related articles for article (PubMed ID: 36068204)
1. MVsim is a toolset for quantifying and designing multivalent interactions.
Bruncsics B; Errington WJ; Sarkar CA
Nat Commun; 2022 Sep; 13(1):5029. PubMed ID: 36068204
[TBL] [Abstract][Full Text] [Related]
2.
Bruncsics B; Errington WJ; Sarkar CA
bioRxiv; 2021 Aug; ():. PubMed ID: 34373856
[TBL] [Abstract][Full Text] [Related]
3. Biosensor-Enabled Deconvolution of the Avidity-Induced Affinity Enhancement for the SARS-CoV-2 Spike Protein and ACE2 Interaction.
Gutgsell AR; Gunnarsson A; Forssén P; Gordon E; Fornstedt T; Geschwindner S
Anal Chem; 2022 Jan; 94(2):1187-1194. PubMed ID: 34964599
[TBL] [Abstract][Full Text] [Related]
4. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics.
Barton MI; MacGowan SA; Kutuzov MA; Dushek O; Barton GJ; van der Merwe PA
Elife; 2021 Aug; 10():. PubMed ID: 34435953
[TBL] [Abstract][Full Text] [Related]
5. Recently Designed Multivalent Spike Binders Cannot Bind Multivalently─How Do They Achieve Enhanced Avidity to SARS-CoV-2?
Erickson HP; Corbin Goodman L
Biochemistry; 2023 Jan; 62(2):163-168. PubMed ID: 35943748
[TBL] [Abstract][Full Text] [Related]
6. Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies.
Mercurio I; Tragni V; Busto F; De Grassi A; Pierri CL
Cell Mol Life Sci; 2021 Feb; 78(4):1501-1522. PubMed ID: 32623480
[TBL] [Abstract][Full Text] [Related]
7. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
[TBL] [Abstract][Full Text] [Related]
8. Structural and Computational Studies of the SARS-CoV-2 Spike Protein Binding Mechanisms with Nanobodies: From Structure and Dynamics to Avidity-Driven Nanobody Engineering.
Verkhivker G
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328351
[TBL] [Abstract][Full Text] [Related]
9. Multivalent Display of SARS-CoV-2 Spike (RBD Domain) of COVID-19 to Nanomaterial, Protein Ferritin Nanocages.
Kalathiya U; Padariya M; Fahraeus R; Chakraborti S; Hupp TR
Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33671255
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic insights into ligand dissociation from the SARS-CoV-2 spike glycoprotein.
Hasse T; Mantei E; Shahoei R; Pawnikar S; Wang J; Miao Y; Huang YM
PLoS Comput Biol; 2024 Mar; 20(3):e1011955. PubMed ID: 38452125
[TBL] [Abstract][Full Text] [Related]
11. Structural basis of SARS-CoV-2 spike protein induced by ACE2.
Meirson T; Bomze D; Markel G
Bioinformatics; 2021 May; 37(7):929-936. PubMed ID: 32818261
[TBL] [Abstract][Full Text] [Related]
12. Dynamics of the ACE2-SARS-CoV-2/SARS-CoV spike protein interface reveal unique mechanisms.
Ali A; Vijayan R
Sci Rep; 2020 Aug; 10(1):14214. PubMed ID: 32848162
[TBL] [Abstract][Full Text] [Related]
13. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.
Choudhury A; Mukherjee S
J Med Virol; 2020 Oct; 92(10):2105-2113. PubMed ID: 32383269
[TBL] [Abstract][Full Text] [Related]
14. In silico investigation of critical binding pattern in SARS-CoV-2 spike protein with angiotensin-converting enzyme 2.
Jafary F; Jafari S; Ganjalikhany MR
Sci Rep; 2021 Mar; 11(1):6927. PubMed ID: 33767306
[TBL] [Abstract][Full Text] [Related]
15. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
[TBL] [Abstract][Full Text] [Related]
16. Exploring Binding Pockets in the Conformational States of the SARS-CoV-2 Spike Trimers for the Screening of Allosteric Inhibitors Using Molecular Simulations and Ensemble-Based Ligand Docking.
Gupta G; Verkhivker G
Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732174
[TBL] [Abstract][Full Text] [Related]
17. Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2.
Ahmad S; Waheed Y; Abro A; Abbasi SW; Ismail S
J Mol Model; 2021 Jun; 27(7):206. PubMed ID: 34169390
[TBL] [Abstract][Full Text] [Related]
18. Exploring the Role of Glycans in the Interaction of SARS-CoV-2 RBD and Human Receptor ACE2.
Nguyen K; Chakraborty S; Mansbach RA; Korber B; Gnanakaran S
Viruses; 2021 May; 13(5):. PubMed ID: 34067878
[TBL] [Abstract][Full Text] [Related]
19. Thermodynamics of the Interaction between the Spike Protein of Severe Acute Respiratory Syndrome Coronavirus-2 and the Receptor of Human Angiotensin-Converting Enzyme 2. Effects of Possible Ligands.
García-Iriepa C; Hognon C; Francés-Monerris A; Iriepa I; Miclot T; Barone G; Monari A; Marazzi M
J Phys Chem Lett; 2020 Nov; 11(21):9272-9281. PubMed ID: 33085491
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a neutralizing antibody that recognizes a loop region adjacent to the receptor-binding interface of the SARS-CoV-2 spike receptor-binding domain.
Anzai I; Fujita J; Ono C; Kosaka Y; Miyamoto Y; Shichinohe S; Takada K; Torii S; Taguwa S; Suzuki K; Makino F; Kajita T; Inoue T; Namba K; Watanabe T; Matsuura Y
Microbiol Spectr; 2024 Apr; 12(4):e0365523. PubMed ID: 38415660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
